US 11,680,247 B2
Platforms and systems for automated cell culture
Matthias Wagner, Cambridge, MA (US); Suvi Aivio, Arlington, MA (US); Mariangela Amenduni, Arlington, MA (US); Catherine Pilsmaker, Arlington, MA (US); Arnaldo Pereira, Cambridge, MA (US); Ananya Zutshi, Boston, MA (US); Anthia Toure, Boston, MA (US); Steven Nagle, Wayland, MA (US); Ozge Whiting, Pawtucket, RI (US); George Harb, Providence, RI (US); Matthew Sullivan, Westwood, MA (US); Maya Berlin-Udi, Acton, MA (US); Stefanie Morgan, Hanover, MA (US); Nick Seay, Charlottesville, VA (US); Sang Lee, Newton, MA (US); and Scott Luro, Somerville, MA (US)
Assigned to CELLINO BIOTECH, INC., Cambridge, MA (US)
Filed by Cellino Biotech, Inc., Cambridge, MA (US)
Filed on Mar. 7, 2022, as Appl. No. 17/688,859.
Claims priority of provisional application 63/311,673, filed on Feb. 18, 2022.
Claims priority of provisional application 63/298,241, filed on Jan. 11, 2022.
Claims priority of provisional application 63/297,290, filed on Jan. 7, 2022.
Claims priority of provisional application 63/295,968, filed on Jan. 3, 2022.
Claims priority of provisional application 63/288,859, filed on Dec. 13, 2021.
Claims priority of provisional application 63/284,839, filed on Dec. 1, 2021.
Claims priority of provisional application 63/282,351, filed on Nov. 23, 2021.
Claims priority of provisional application 63/249,698, filed on Sep. 29, 2021.
Claims priority of provisional application 63/239,995, filed on Sep. 2, 2021.
Claims priority of provisional application 63/226,128, filed on Jul. 27, 2021.
Claims priority of provisional application 63/222,059, filed on Jul. 15, 2021.
Claims priority of provisional application 63/216,558, filed on Jun. 30, 2021.
Claims priority of provisional application 63/210,243, filed on Jun. 14, 2021.
Claims priority of provisional application 63/196,904, filed on Jun. 4, 2021.
Claims priority of provisional application 63/194,306, filed on May 28, 2021.
Claims priority of provisional application 63/167,114, filed on Mar. 28, 2021.
Claims priority of provisional application 63/157,731, filed on Mar. 7, 2021.
Prior Publication US 2022/0282223 A1, Sep. 8, 2022
Int. Cl. G06K 9/00 (2022.01); C12N 5/074 (2010.01); C12N 5/00 (2006.01); G06T 7/00 (2017.01); C12M 1/00 (2006.01); C12M 3/00 (2006.01); C12M 1/34 (2006.01); C12M 1/36 (2006.01); C12M 1/12 (2006.01); C12M 1/06 (2006.01); C12M 1/26 (2006.01); G01N 15/10 (2006.01); B01L 3/00 (2006.01)
CPC C12N 5/0696 (2013.01) [B01L 3/502715 (2013.01); C12M 23/14 (2013.01); C12M 23/22 (2013.01); C12M 23/26 (2013.01); C12M 23/28 (2013.01); C12M 23/42 (2013.01); C12M 23/44 (2013.01); C12M 23/48 (2013.01); C12M 25/06 (2013.01); C12M 27/02 (2013.01); C12M 29/02 (2013.01); C12M 33/00 (2013.01); C12M 33/12 (2013.01); C12M 41/12 (2013.01); C12M 41/26 (2013.01); C12M 41/44 (2013.01); C12M 41/46 (2013.01); C12M 41/48 (2013.01); C12M 47/04 (2013.01); C12N 5/0081 (2013.01); G01N 15/1056 (2013.01); G06T 7/0012 (2013.01); G06T 7/0016 (2013.01); B01L 2300/0663 (2013.01); G01N 2015/1006 (2013.01); G06T 2207/10056 (2013.01); G06T 2207/10064 (2013.01); G06T 2207/20081 (2013.01); G06T 2207/30024 (2013.01); G06T 2207/30072 (2013.01)] 23 Claims
OG exemplary drawing
 
1. A method for producing a monoclonal induced pluripotent stem cell (iPSC) product, comprising:
(a) placing input cells in a cell culture chamber of a closed cell culture container;
(b) reprogramming at least a portion of the input cells into a plurality of clonal iPSC candidate cells;
(c) acquiring, using an image sensor, image data of a plurality of clonal iPSC candidate cell colonies emerging from the plurality of clonal iPSC candidate cells;
(d) processing, by a computer processor, the acquired image data using a trained machine learning model to predict clonal functionality of the plurality of clonal iPSC candidate cell colonies, wherein the trained machine learning model is trained with clonal iPSC functionality assay data;
(e) selecting, by the computer processor, at least one of the plurality of clonal iPSC candidate cell colonies for expansion based at least in part on the predicted clonal functionality of the plurality of clonal iPSC candidate cell colonies;
(f) removing non-selected clonal iPSC candidate cell colonies of the plurality of clonal iPSC candidate cell colonies from the cell culture chamber using a cell editor; and
(g) expanding the selected at least one of the clonal iPSC candidate cell colonies into the monoclonal iPSC product.